ClinicalTrials.gg

Program

pediarix

Also written as “Pediarix”, “Infanrix™ penta” and “Infanrix penta”.

Its studies are mostly in Haemophilus Infections · Rotavirus Infections · Hepatitis B, led by 2 companies.

Furthest: phase 3, since Feb 9, 20069 company-led studies, 1 open or runningNext primary completion: Nov 6, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline80 open or runningphase 3since Feb 9, 2006Aug 10, 2005none ahead
Pfizer11 open or runningphase 3since Aug 14, 2025Aug 14, 2025Nov 6, 2028phase 3 · NCT07160244

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 10, 2005First study: phase 2 study in Haemophilus InfectionsNew to GlaxoSmithKlineGlaxoSmithKline · NCT00129116 · 388 enrolled · Belgium, Germany
  2. Feb 9, 2006Phase 3 study in Haemophilus InfectionsGlaxoSmithKline · NCT00289783 · 4,441 enrolled · United States, Australia, Mexico
  3. May 4, 20062 phase 3 studies in Haemophilus InfectionsGlaxoSmithKline · NCT00322335, NCT00327184
  4. Apr 19, 2007Phase 3 study in Hepatitis BGlaxoSmithKline · NCT00463437 · 1,437 enrolled · Germany, Poland, Spain
  5. Dec 21, 2007Phase 3 study in Haemophilus InfectionsGlaxoSmithKline · NCT00586612 · 313 enrolled · Spain
  6. Oct 22, 2009Phase 3 study in Haemophilus InfectionsGlaxoSmithKline · NCT01000974 · 4,003 enrolled · United States
  7. Jun 16, 2017Phase 3 study in Rotavirus InfectionsGlaxoSmithKline · NCT03207750 · 1,280 enrolled · United States
  8. Aug 14, 2025Pfizer's first study: phase 3 study in HealthyNew to PfizerPfizer · NCT07160244 · 6,000 planned · United States, Argentina, Brazil and more

Ahead

  1. Nov 6, 2028Primary completion: phase 3 study in HealthyPfizer · NCT07160244

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“A vaccine consisting of detoxified tetanus toxoid, detoxified diphtheria toxoid, acellular pertussis antigens, inactivated poliovirus (IPV) types 1,2 and 3 and hepatitis B (HBV) surface antigen, with active immunizing activities against diphtheria, tetanus, pertussis, hepatitis B, and poliomyelitis”NCIt, by rule

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07160244Healthy · United States, Argentina, Brazil and more3RecruitingPfizerNov 6, 20286,000
NCT03207750Rotavirus Infections · United States3CompletedGlaxoSmithKlineOct 9, 20181,280
NCT01000974Haemophilus Infections · United States3CompletedGlaxoSmithKlineNov 18, 20114,003
NCT00586612Haemophilus Infections · Spain3CompletedGlaxoSmithKlineDec 30, 2008313
NCT00463437Hepatitis B · Germany, Poland, Spain3CompletedGlaxoSmithKlineJan 21, 20081,437
NCT00327184Haemophilus Infections · Finland, Italy3CompletedGlaxoSmithKlineNov 2006709
NCT00322335Haemophilus Infections · Spain3CompletedGlaxoSmithKlineJul 2006230
NCT00289783Haemophilus Infections · United States, Australia, Mexico3CompletedGlaxoSmithKlineAug 27, 20074,441
NCT00129116Haemophilus Infections · Belgium, Germany2CompletedGlaxoSmithKlineDec 1, 2003388

How it is read

Names in the registry

  • “Pediarix”, 3 entries
  • “Infanrix™ penta”, 2 entries
  • “Infanrix penta”, 1 entry
  • “Infanrix penta ®”, 1 entry
  • “Pediarix™”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.